| Logo | Name | Σ | Employees |
|---|---|---|---|
 | ROTOP Pharmaka GmbH ROTOP Pharmaka is a leading German pharmaceutical company that produces cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries worldwide. With almost 20 years of experience in the development, production, authorization and distribution of sterile kits for radiolabeled pharmaceuticals ROTOP continuously expands its product portfolio by developing new products and entering new strategic partnerships. Nuclear Medicine, Molecular Imaging, SPECT, CDMO services, Ga68, PET, radiopharmaceutcials, Tc99m, cold kits, GMP manufacturing, Regulatory Affairs, Medical Affairs, Distribution, Q-Unit, Pharmaceutical Development, Ready-to-use-radiopharmaceutcials, Supply, Packaging & Labelling, Logistics, Quality Assurance, Quality Control, Qualified … Type: | 0 | 71 |
 | AnaCardio AnaCardio is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022. You can find more information about AnaCardio at www.anacardio.com. Type: | 0 | 23 |
 | StemSight - Vision Unlimited Curing blindness with regenerative cell therapies. StemSight develops off-the-shelf regenerative cell therapies for corneal blindness. Our expertise is in the combination of iPS-derived cells with functional biomaterials - for FASTER tissue regeneration, SAFER cell therapies and EASIER cell delivery. Type: | 1 | 16 |
 | CoreMedic straight to the heart CoreMedic is dedicated to develop devices and therapies to dramatically improve the quality of life of patients with heart valve diseases, a primary challenge in global healthcare. CoreMedic’s flagship product ChordArt is a transfemoral system for mitral valve chordal repair in the beating heart. ChordArtTM offers a first line therapy option for patients with mitral valve dysfunction and represents a less invasive procedure compared to the current surgical methods with open-chest or trans-apical access. ChordArt is designed to allow mitral repair in a wider patient population. ChordArtTM is currently under clinical evaluation in European clinics. CoreMedic … Type: | 0 | 13 |
 | Harness Therapeutics Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases neurodegeneration, RNA therapeutics, physiological upregulation, post-transcriptional upregulation, mRNA, ASO, and SINEUP Type: | 0 | 30 |
 | AlzeCure Pharma Developing groundbreaking treatments for Alzheimer’s disease, pain conditions and other severe CNS disorders. Learn more AlzeCure Pharma is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease and pain. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such … Type: | 0 | 15 |
 | Aplagon Pioneering First-in-Class Treatments for Thromboinflammatory Diseases Founded on pioneering research by Riitta Lassila and associates at the Wihuri Research Institute in Helsinki, Aplagon is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapeutics for thromboinflammatory diseases, addressing critical unmet medical needs in vascular medicine. Its lead therapeutic, APAC, a heparin proteoglycan mimetic, is a dual AntiPlatelet and AntiCoagulant (APAC) with unique antithrombotic and anti-inflammatory properties. Designed to specifically target vascular injury sites, APAC provides localized, long-term action while minimizing systemic exposure. The company’s clinical pipeline focuses on addressing thromboinflammatory conditions, with lead indications in arteriovenous fistula (AVF) maturation failure for … Type: | 0 | 6 |
 | Akribion Therapeutics A new class of cancer therapies using RNA-guided nucleases for specific cell depletion Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E payload has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence, ensuring that only the targeted cells are affected, leaving healthy cells unharmed. Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), Akribion is exploring additional applications in oncology, autoimmune diseases, fibrosis, and infectious diseases. The flexibility and broad potential of Akribion's … Type: | 0 | 16 |
 | Enduro Bioproduction at scale Enduro is a biotech startup improving large-scale fermentations. We help biotech companies enhance large-scale fermentations, bringing products cheaper and faster to market. Our proprietary platform Enduro Sense reprograms cells to improve population heterogeneity and endurance of production. Enduro Sense is seamlessly integrated, self-selecting technology that addicts microbial cells to production. EnduroSense is easily integrated across host organisms. We welcome inquiries to test Enduro Sense. Get in touch at info@endurogenetics.com or visit our website. Type: | 0 | 24 |
 | Verdiva Bio Transforming lives by accelerating innovation in cardiometabolic health Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. … Type: | 0 | 34 |
 | Ysium Medical Innovation We provide new technological solutions for the medicine of the future. We provide new technological solutions for the medicine of the future. We merge engineering, medicine and design to create medical devices that solve real needs. Type: | 0 | 8 |
 | Arctic Therapeutics Accelerating treatments for millions of patients Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development, as well as sharply reducing the enormous cost and time to bring effective treatments to millions of patients. AT leverages over 20 years of international genomics research, pioneering a novel approach to guide its drug development. The company collaborates closely with The Center for Applied Genomics (CAG) at the Children’s Hospital of Philadelphia to repurpose and develop ground-breaking new medical treatments. AT-001, AT's Alzheimer‘s drug candidate, has the potential to become the first cure for dementia, not … Type: | 1 | 17 |
 |  Airnov Healthcare Packaging Protecting Today, Preserving Tomorrow Protecting Today, Preserving Tomorrow. Type: | 0 | 126 |
 | NEOMED Services Your asset in design validation and regulation of medical devices Type: | 0 | 1 |
 | Grillido GmbH Enjoyment with a clear conscience and strong nutritional values. At Grillido we attach particular importance to high -quality raw materials and a balanced nutritional profile for our products. We are proud to enable pleasure without giving up, be it through our delicious sausages for meat lovers, protein-rich grill cheese for cheese fans or a variety of veggie alternatives. Our goal is to promote a healthier future and to inspire customers with the best taste experiences. We rely on quality and innovation. Type: | 0 | 8 |
 |  XING Technologies XING Technologies has a clear vision in applying diagnostic nanotechnologies to globally enhance healthcare systems. We are an Australian-owned and operated cancer pathology lab that uses genetic sequencing to inform doctors and patients about precision cancer treatment options. Precision medicine offers cancer patients therapy options that are targeted specifically to their cancer. XING Genomic Services offers a range of cancer genetic tests for both newly diagnosed cancer patients and patients dealing with a recurrence of their disease. The results analysed in our lab will determine whether the genetic alterations found in your cancer match genetic changes that are associated with … Type: | 0 | 3 |
 | PrimeCell Advanced Therapy, a.s. PrimeCell Therapeutics is a Czech biotechnology society focused on regenerative medicine and modern therapy aimed at developing and producing medicinal products of modern therapy (Advanced Therapies Medicinal Products) that increases people's quality of life. Primecell Therapeutics was founded in 2007 to build a worldwide competitive Hi-Tech centers in the Czech Republic, which will be involved in the global development process of modern and cellular therapy. PrimeCell Therapeutics allows doctors and patients new methods of treatment that use human cells and new materials such as nanomaterials to treat serious diseases. Thanks to the unique know-how in modern therapy, biotechnology and nanotechnology, … Type: | 0 | 17 |
 | Kinoxis Therapeutics Pty Ltd Kinoxis Therapeutics Pty Ltd is a private, Australian-based, clinical-stage biotechnology company developing first-in-class therapeutics to address the escalating demand for safe and effective treatments for behavioural and psychological symptoms in neuropsychiatric disorders. Kinoxis’ lead candidate, KNX100, is being developed for the treatment of behavioural and psychological symptoms in neuropsychiatric disorders, including agitation and aggression in dementia, and several substance use disorders. KNX100 has a novel mechanism of action, interacting with disease relevant pharmacological, molecular, and neural targets, to modify the dysregulated brain systems linked with specific behavioural and psychological symptoms in neuropsychiatric disorders. The compound has an extensive pre-clinical data … Type: | 1 | 16 |
 |  TB TB is an internet company. Type: | 6 | 1,080 |
 | Spectroplast AG Breaking boundaries by leading the industrial revolution in unprecedented elastomer solutions Spectroplast is an On-Demand Service Provider for end-use silicone products that are functional and perform. What many industries have tried for years, Spectroplast has achieved with Silicone Additive Manufacturing, making silicones accessible to Industry 4.0. For the first time, end-use silicone products are directly fabricated without the use of molds, saving costs, time while offering an unprecedented freedom of design: - Shore Hardness A20, A35, A50 and A60 - Highest precision 3D Printing, Silicone, Silicone 3D Printing, Soft materials, High precision 3D printing, Additive Manufacturing, Medical, Manufacturing, Technical, Healthcare, … Type: | 3 | 14 |
 | LiveDrop Bio We create all-in-one instruments that make high-throughput single-cell workflows easy thanks to droplet microfluidics At LiveDrop, we develop, build, and sell cutting-edge instruments and methods for high-throughput screening of biological cells and organisms—down to the single-cell level—using microfluidic droplets. Our solutions enable faster, more precise screenings through highly efficient, fully integrated bioassays. LiveDrop’s flagship platform, ModaFlow 4L5C, revolutionises cell screening, drug discovery, and secretome analysis with unparalleled speed and precision. It supports a wide range of applications, including monoclonal antibody discovery, single-cell secretome-based bioassays, high-throughput spheroid manufacturing for drug testing, directed evolution of microbes, and enzyme discovery. We value collaboration … Type: | 3 | 15 |
 | MicroOmix We give access to the pulse of life Unlocking the Future of Cell Screening with Groundbreaking Innovation MicroOmix is a pioneering startup powered by patented technology from the CNRS and the University of Strasbourg, setting a new standard in high-throughput cell screening. Our cutting-edge platform analyzes cells based on the molecules they secrete, with a level of precision and resolution that is unrivaled. Secreted molecules are at the heart of critical biological processes—driving immune responses, cell migration, tissue regeneration, and differentiation. Emerging research reveals their pivotal role in disease progression and therapeutic effectiveness, but until now, accessing these insights has … Type: | 4 | 5 |
 | German Bionic We got your back – Smart tools for the future of human physical work. German Bionic is a European robotics firm that develops and manufactures smart power suits and other wearable technologies. It was the world’s first company to deliver connected exoskeletons for the workplace, applying self-learning and artificial intelligence to support lifting movements and prevent poor posture, and thereby becoming an intelligent link between humans and machines. The German Bionic smart power suits and wearables protect the health of workers and markedly reduce the risk of accidents and injury to consequently improve work processes. In recognition of this innovative … Type: | 13 | 78 |
 | Enovis Clinically differentiated solutions that enhance patient outcomes and restore motion for life. We’re EnovisTM – a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We strive to make each day better by partnering with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. We do this through our extraordinary talent, a relentless focus on innovation, strategic acquisitions, and a common culture of continuous improvement. With more than 7,000 incredible … Type: | 3 | 135 |
 | Comphya Providing a better solution for non-responders to oral drugs. Comphya is a Swiss medical device company, spin-off from the Swiss Federal Institute of Technology (EPFL). Its mission is to overcome the major clinical problems of erectile dysfunction (ED) in spinal cord injury and post-prostatectomy patients (non-responders to oral drugs). Our innovation lies on neuroprosthetics principles and will offer a unique and superior treatment for ED. Our goal is to fulfill patient needs through safe and effective medical devices, offering life quality in large parts of the male population in great need. Urology, Medical Devices, Neuroprosthetics, and Erectile Dysfunction Type: | 1 | 8 |
 | Aseptuva Aseptuva is a Medtech startup with the aim to prevent hospital acquired infections using safe Far-UVC light. We are developing a series of medical devices in the Class II (a,b) category, for in-situ disinfection of catheters and tubes inserted into patients inside an ICU environment, as well as on the outside. Our automated and targeted solution strives to prevent secondary infections in hospitals such as VAP, CLABSI etc, thereby reducing the burden on healthcare workers, and improving the overall patient experience by shortening hospital stay and saving additional costs. Type: | 6 | 8 |
 | INCAPTEK Ultra-performance materials for various industries, from electronics, automotive and aerospace to BioTech/MedTech INCAPTEK Sàrl is a start-up from Switzerland developing advanced drug delivery systems and technologies to produce high-performance materials. We design smart micro(nano)encapsulation solutions and highly innovative materials for controlled and targeted drug delivery for biotech and medtech industries. We deliver drugs at the right place, in the right dosage, and at the right time, bringing treatment outcomes to the next level. Our technologies can be used as a standalone drug delivery platform for pharmaceuticals and genetic material, as well as for drug-eluting coatings for implantable medical devices and … Type: | 0 | 2 |
 | VitroLabs Inc Harnessing science and nature to cultivate authentic materials starting with slaughter-free cultivated leather. We cultivate authentic materials without compromise,by harnessing science and nature responsibly by partnering the most innovative minds in science and technology with the finest craftspeople to accelerate the use of cellular agriculture for good. Our first product is slaughter-free, real leather. cellular agriculture, tissue engineering, leather, luxury leather, lab-grown, cultivation, Bioprocessing, and bioreactor Type: | 4 | 8 |
 | MedFacts Drug discovery with cutting-edge AI technology We’re pioneering the use of AI and shaping the future in drug discovery, significantly cutting costs and development times. Our unique AI algorithms have generated novel drug candidates and identified enhancements for existing therapies more efficiently than traditional methods, setting us apart in the competitive landscape. Artificial Intelligence, Data Science, Health, Medicines, and Drug development Type: | 0 | 1 |
 | Zendia GmbH Revolutionize Diagnostics - Eliminate Malaria At Zendia we are committed to developing ultra sensitive POC (Point-Of-Care) diagnostic technologies in order to readily and easily detect infectious diseases at an early stage. By efficiently detecting infections earlier, targeted treatment can be offered to patients sooner - not only decreasing the burden on healthcare systems, but ultimately leading to many lives saved. At Zendia, we offer innovative solutions for global health problems. One major global health problem is malaria, which is a life-threatening disease caused by Plasmodium parasites. Malaria is one of the most severe public health problems worldwide, and is a … Type: | 0 | 3 |
 | LaNua Medical LaNua Medical is a medical device company that develops disruptive image-guided technologies. Type: | 0 | 4 |
 | PeptiSystems AB A new generation of flow-through instruments for solid-phase synthesis of peptide and oligonucleotide therapeutics. PeptiSystems offers a new generation of flow-through instruments for solid-phase peptide and oligonucleotide therapeutics synthesis. Based on flow-through column technology, our instruments are used within the biopharmaceutical and biotech industry for process development and large-scale GMP and non-GMP manufacturing. Chemistry first - our instruments are designed from a chemistry perspective to give maximum flexibility and control without compromise. Peptide Synthesis, Oligonucleotide Synthesis, Flowthrough column technology, Continuous flow, Organic chemistry, and Synthesis instruments Type: | 0 | 13 |
 | Suprema Enabling HTS SUPREMAcy Suprema has been founded in 2024 to manufacture the best-in-class High Temperature Superconducting tapes to enable major breakthroughs in multiple applications such as: Magnetic Fusion Reactors (where Superconductors play the role of enabling technology), Electric Grid (transmission, distribution and conversion of electricity), Next Generation Physics Experiments (as future colliders or high field magnets), Bio-Medical devices (as NMR and MRI), Electrical aircrafts and ships and more... Working to enable the HTS SUPREMAcy Type: | 0 | 6 |
 | ViGeneron GmbH Dedicated to develop the medicines of the future ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich. At ViGeneron we are dedicated to develop innovative gene therapies based on our two unique and proprietary technology platforms. ViGeneron will leverage its two technology platforms to address unmet medical needs with in-house gene therapy programs for selected retinal disorders. Together with partners we will exploit our ViGeneron technologies for additional indications. Gene Therapy, Inherited Retinal Disorders, and AAV vector Type: | 0 | 10 |
 | Corify Solving cardiac arrhytmias. Spinoff funded by EIT Health CORIFY Care is a start-up funded by main world-wide experts on cardiac arrhythmias which is going to introduce in the market a novel medical device to non-invasively map cardiac arrhythmias in real time. This novel technology will improve the treatment in more than 10 million of atrial fibrillation patients only in Europe. Our non-invasive electro-anatomical mapping systems displays the activation patterns in each point of the heart without the need of invasive catheters, allowing the possibility to map all atrial fibrillation patients even during a regular visit to the cardiologist. CORIFY care … Type: | 0 | 22 |
 | Concinnity Genetics Improving the safety and efficacy of gene therapies using AI Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration. Gene Control, RNA, Artificial Intelligence, Synthetic Biology, and … Type: | 0 | 5 |
 | aptaTargets Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases Type: | 1 | 11 |
 | AGECURVE LIMITED Cell Tree Analytics, somatic mutation tracking, clonal structure quantification, check out our Cell Tree Rings study here https://www.biorxiv.org/content/10.1101/2022.12.14.520419v1 mass spec proteomics, aging Type: | 1 | 1 |
 | Kyomei Animal Identical, Plant Grown Kyomei is a molecular farming and biotechnology start-up that focuses on the production of animal-identical proteins, pigments, ingredients and molecules using the power of plants, photosynthesis, and molecular biology. We aim to fundamentally transform agriculture and the food industry by decoupling the deleterious impact of animal agriculture from its byproducts and offering a more compelling, lower cost and sustainable means of production. Animal-identical benefits. Plant-grown production. Agtech, Bioengineering, Molecular Farming, Alternative Protein, Ingredients, Innovation, Biotechnology, Foodtech, Plant-based, Plant Molecular Farming, Genetic Editing, CRISPR, Downstream Processing, Plant Transformation, Protein, Protein Extraction, and Leaf Protein Type: | 0 | 10 |
 | Revance Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Botulinum Toxin, biotechnology, biotech, healthcare, pharmaceuticals, science, research, financial services, and fintech Type: | 4 | 602 |
 | BetaGlue Therapeutics Precision Radiotherapy From Within BetaGlue Therapeutics is a clinical stage oncology company that has developed an advanced radiotherapy platform enabling localised targeted treatment of both unresectable solid tumours and also treatment of surgical resection margins called YntraDose. radiotherapy, nuclear medicine, oncology, and medical devices Type: | 0 | 16 |
 | Essential Pharma For some patients we are essential Essential Pharma is an international specialty pharmaceutical company dedicated to maintaining access to clinically differentiated, niche medicines in small patient populations. Our high-impact portfolio has a focus on the central nervous system (CNS), gastroenterology, ophthalmology, and rare disease, and our products treat patients in more than 70 countries. We are proactive in identifying low volume, difficult-to-manufacture therapeutic products, and late-stage clinical development assets that target rare diseases. We specialise in the acquisition of mature, established, branded medicines that are at risk of shortages or discontinuation, working with partners across the globe to ensure their … Type: | 0 | 85 |
 | NewAmsterdam Pharma Corporation NewAmsterdam Pharma Corporation is a clinical-stage biopharma company creating therapies for cardiometabolic diseases. This page is intended for US audiences. Founded in 2019, NewAmsterdam Pharma Corporation is a late-stage clinical biopharmaceutical company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. The Company is investigating a selective cholesteryl ester transfer protein (CETP) inhibitor as an LDL-C lowering therapy for patients who cannot be treated optimally with currently available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia … Type: | 1 | 46 |
 | Biofrontera Group We aim to protect and heal your skin with our innovative photodynamic therapy medication. Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Germany-based company develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In the EU, the company … Type: | 0 | 89 |
 | ADVANZ PHARMA Partner of choice in specialty, hospital, and rare disease medicines Partner of choice in specialty, hospital, and rare disease medicines ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing the specialty, hospital, and rare disease medicines they depend on. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with innovative biopharma and pharmaceutical development companies to bring medicines to patients. Headquartered in London, UK, we have commercial sales in more … Type: | 1 | 657 |
 | Mainstay Medical First and Only FDA Approved Restorative Therapy for Chronic Mechanical Low Back Pain Mainstay Medical, led by a team of dedicated scientists, executives, engineers, and clinical experts, brings to you ReActiv8®, the first and only FDA-approved restorative treatment for mechanical chronic low back pain. RESTORE Control RESTORE Function RESTORE Stability ReActiv8 LIFE The Company was incorporated in Dublin, Ireland and headquartered in San Diego, CA. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands. Type: | 1 | 149 |
 | i-MEDS Healthcare i-MEDS Healthcare - Innovative Medication Delivery Solutions. i-DoneaTM from i-MEDS Healthcare is the e-Health solution that makes taking medication at home easier and safer. i-DoneaTM is an extension of drug delivery circuit from the pharmacy to home. i-DoneaTM is an intelligent medication dispenser, connected 24/24 and designed to accurately and unfailingly administer the vital medications people require every day. i-DoneaTM, a unique & innovative product: - Simple & user-friendly design - Large touch-sensitive user interface- Innovative use for an extension of the drug delivery circuit at home- Technical innovation- 3-pronged approach: Therapeutic Education / Simplification / Automation, i-DoneaTM de i-MEDS … Type: | 11 | 6 |
 | Bionest Partners Bionest Partners is a global consulting firm focused on Pharma, Biotech, Medical Device and Diagnostics that helps clients navigate complex product development issues in order to drive growth, create value and gain competitive advantage. We also offer our expertise and analytic skills to support investors with due diligence assignments in these markets. Bionest consultants are valued strategic partners who have helped more than 250 companies around the world build high-value product portfolios, optimize development approaches and prepare for commercial success. Our track record includes more than 500 successful projects consisting of innovative, creative and differentiated action plans grounded in in-depth … Type: | 2 | 34 |
 | CardioSignal by Precordior CardioSignal is developing a disruptive mobile application-based technology to improve the detection of heart disease. CardioSignal is a health technology company developing groundbreaking solutions for early detection of heart diseases. We are based in Turku, Finland and Palo Alto, CA, United States. The CardioSignal mobile application is a CE-marked class IIa medical device for the detection of atrial fibrillation, available in over 10 countries. The technology we are developing enables a digital cardiac biomarker for other major heart diseases as well. CardioSignal is a brand and a product by Precordior. Originally an academic spinoff, the company’s patented motion sensor technology … Type: | 1 | 30 |
 | FreeOx Biotech Pioneering Next-Generation Stroke Treatments FreeOx Biotech: Advancing Stroke Care through Innovation and Precision Medicine FreeOx Biotech is a pioneering late-stage clinical biotechnology company dedicated to transforming acute ischemic stroke (AIS) management. Our mission is to improve outcomes for stroke patients through the discovery and development of Cerebrovascular Protective Therapeutics. Our lead asset, Ox-01, is a Phase 3-ready investigational drug with breakthrough potential as an emergency adjunct therapy to Mechanical Thrombectomy. Selected by the prestigious StrokeNet Thrombectomy Endovascular Platform (STEP) program, funded by the National Institute of Neurological Disorders and Stroke (NINDS), Ox-01 represents a paradigm shift in AIS treatment. Backed … Type: | 0 | 5 |
 | Rethink Medical SL. Rethink Medical S.L. is a start-up company dedicated to the development of new medical devices in the nursing field. Rethink Medical is a Spanish startup company focused on developing innovative medical devices, mainly in the nursing field, based on real life experiences regarding both patient needs and common hospital procedures. Our first patented product is a urinary catheter We are working on other continence-related projects as well, improving healthcare processes and patient comfort due to the aging of the population and the increased need for these products. Type: | 0 | 6 |
 | Probably Genetic Helping people with rare genetic diseases get answers. Probably Genetic helps undiagnosed rare disease patients find answers to their symptoms in a matter of weeks. There are over 400 million people worldwide that have a rare disease — more than cancer and HIV patients combined. Half of those patients are currently undiagnosed and half of them are children, and it takes 5-7 years on average for these patients to get a diagnosis. With our system, patients can get answers in a matter of weeks. Our online Symptom Checker identifies rare disease patients using state-of-the-art machine learning models, gets them tested … Type: | 0 | 29 |
 | Asahi Kasei Bioprocess America, Inc. Pioneering Biologics Safety and Manufacturing Efficiency As a global partner to the biopharmaceutical industry, Asahi Kasei Bioprocess helps biologics manufacturers safely and efficiently produce medicines that patients can trust, by dependably supplying innovative yet exceptionally reliable bioprocess consumables, equipment and scientific support services. Our portfolio is anchored by PlanovaTM virus removal filters. First released in 1989 as the world's first hollow fiber filter developed specifically for removing viruses from biotherapeutic drug products, PlanovaTM filters ensure viral safety of biopharmaceutical drug products, thanks to their high quality and consistent performance. Leveraging 30 years of experience, we continue to provide our customers … Type: | 0 | 127 |
 | Maze Therapeutics At Maze, we envision a world where genetic insights inspire new medicines. Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. The company’s pipeline is led by two wholly owned lead … Type: | 2 | 137 |
 | Tetra Therapeutics, a SHIONOGI Group Company Follow us at Shionogi Inc. for news about our rare disease research programs https://www.linkedin.com/company/shionogi-inc-/ drug discovery, PDE4D, PDE4B, Fragile X, CTE, Rubinstein-Taybi, traumatic brain injury, Clinical Trials, Fragile X syndrome, Cognition, BPN14770, and Memory Loss Type: | 1 | 5 |
 | Qpex Biopharma Focusing on Resistance in Antibiotic Development Qpex Biopharma, Inc. a Shionogi Group Company, is a resistance-focused infectious disease company on a mission to make both a dramatic and sustainable improvement in patient care. Leveraging a multi-faceted approach and a deep understanding of drug resistance mechanisms, we are creating novel products and development. strategies that overcome multi-drug resistance. We are advancing a robust portfolio of treatments that will bring innovation to antibiotic development and deliver the right treatments to the right patients in the right settings. During the previous decade, our team brought 4 antibiotic products to regulatory approvals, with an … Type: | 1 | 31 |
 | Kelonia Therapeutics Revolutionizing in vivo gene delivery to usher in a new era of genetic medicines. Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal … Type: | 2 | 59 |
 |  CellSine Discover your favorite frequencies to boost your drug discovery business CellSine provides devices and software that make advanced electrochemical impedance spectroscopy easily accessible to any microbiological researcher. It delivers a platform tool for a that enables a wide variety of biochemical studies. Biotechnology, Cell culture monitoring, Proteïn - Proteïn interactions, Suspension cultures, Receptor signaling, Biofilm maturation, and T lymphocyte activation Type: | 1 | 4 |
 | Koatum An innovative solution for medical implants Koatum is a MedTech startup that developed a medical implant coating technology for dental and orthopaedic implants. Koatum prevents inflammation and accelerates bone integration, for a faster, painless recovery. Technology provides opportunity to coat any materials which could not be coated with plasma sputtering due to the high temperatures involved. An inert first layer is ensuring perfect formation between implant and coating. Upper layers, made from hydroxyapatite without the intense heat used in plasma coating, remain bioactive and durable. Technology also provides the ability to implement drug delivery systems. With Koatum technology surgeon can … Type: | 0 | 2 |
 | Cyclica (acquired by Recursion, Nasdaq: RXRX) From molecule to medicine Unlocking the protein universe to discover the medicines of tomorrow Cyclica has been acquired by Recursion! Please follow @Recursion on LinkedIn and @RecursionPharma on Twitter to receive updates on our next chapter. Drug Development, Network Pharmacology, Drug Repositioning, Proteomics, Clinical Trials, Side Effects, Bioinformatics, Systems Biology, Drug Discovery, Artificial Intelligence, polypharmacology, medicines, Machine learning, pharmacology, pharmaceuticals, and bioinformatics Type: | 20 | 4 |
 | Creativ-Ceutical Creativ-Ceutical provides strategic pricing, market access and health economics consulting in life sciences. We provide both the strategic advice and the technical services to deliver results that meet your expectations. We have broad experience in the areas of central nervous system (CNS), oncology, vaccines, metabolic/cardiovascular diseases, and rare diseases. These are complex and developing fields, where treatment paradigms are in constant evolution and where clinical and economic issues require rigorous analysis to determine the best therapeutic choices. This experience allows us to address the most complex challenges and to anticipate pricing and market access issues that will arise in other … Type: | 0 | 83 |
 | Perfood Prescription digital therapeutics powered by personalized nutrition. Reimagining medicine At Perfood, we translate state-of-the-art data and medical science into therapy. We create software, that precisely identifies what actions need to be take on a personalized level, to prevent or fight diseases. Using sensors, lab results and holistic analyses, we derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. We call this approach digital therapeutics. A digital solution that is just as effective as a drug. But without side effects. We believe that our genetic heritage is an elementary compound of our health. … Type: | 2 | 100 |
 | Graph Therapeutics Improving the lives of patients with immune-mediated diseases through Al-driven precision medicine Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of patients are left without adequate treatment options - and AI trained with complex disease data can solve this. Type: | 0 | 9 |
 | MIP Pharma Group Working to keep you healthy. The MIP Pharma Group (MIP Pharma) produces and sells prescription-only generics, specifically antibiotics, over-the-counter medicines and medical devices. The main markets are Germany and Poland and some other Eastern European markets. MIP Pharma has two production facilities in Saarland/Germany. With around 250 employees, MIP Pharma realised a total turnover of more than €40 million during the last business year. Contact: info@mip-pharma.de Generika, Antibiotika, OTC-Arzneimittel, and Medizinprodukte Type: | 1 | 114 |
 | Eurofins Discovery Eurofins Discovery offers you a complete, single-source solution for drug discovery products and services. Eurofins Discovery has supported Drug Discovery research for >40 years. Our partners inspire us to innovate in the pursuit of life-changing cures. We provide our experience, depth, and breadth in the form of innovative testing services and product tools that support researchers as they accelerate the discovery and development of candidate molecules. Our global team of dedicated scientists, information analysts, and client support professionals make this mission possible. Our focus drives us to continually expand our portfolio of testing methods, tools, and services to enable real, … Type: | 2 | 206 |
 | ABL ABL Europe is now part of the OXB Group More info at : oxfordbiomedica.com ABL Inc remains part of the Institut Mérieux Group More info at ablinc.com Type: | 5 | 503 |
 | Five Alarm Bio Limited Boosting the body's ability to defend against the damage of aging Five Alarm Bio is a drug discovery company based in Cambridge, UK focusing on novel approaches to anti-aging, with broad potential therapeutic application. We are researching therapeutics that boost the body's ability to defend against the damage of aging. Type: | 0 | 5 |
 | Limula Cell & Gene Therapy: Automated. Scalable. Accessible Limula provides an innovative solution for the production of the most personalised cancer treatments on demand and at scale. Our product is a unique proprietary platform can perform multiple steps of cell therapy manufacturing in a single device, using end-to-end automation and integrated process analytics. Bioproduction, Immunooncology, Cell therapy, Biotechnolgoy, Manufacturing, and CAR-T Type: | 3 | 29 |
 | FIRE1 Our purpose is to help millions of people living with heart failure to get their normal back. FIRE1 aims to improve patient quality of life, and patient outcomes, while lowering overall healthcare costs. Health Tech, Research & Development, Medical Devices, Software Engineering, and Clinical Type: | 4 | 69 |
 | CompagOs Pioneering Solutions to Understand, Diagnose, and Treat Bone Conditions CompagOs is bringing better bone health to all by empowering researchers to transform discoveries into clinical applications, while enabling physicians to match patients with the right treatments and support faster recovery. At the core of our mission are our biologically relevant and reproducible Bon3OIDTM in vitro bone models, developed using state-of-the-art 3D bioprinting. Leveraging this technology, we are currently focused on developing a blood-based assay to detect bone metastases earlier than existing imaging methods, representing a key step toward advancing bone health. Additionally, we provide comprehensive services to academic researchers and … Type: | 1 | 5 |
 | Causeway Therapeutics Healthy Ageing Through Musculoskeletal Health Maintaining musculoskeletal health is the keystone of overall health as we get older. As we age our physical condition gradually deteriorates, leading to loss of strength, fitness and mobility. In most cases, this isn’t due to a simple decision to stop exercising. It is due to the breakdown of musculoskeletal function caused by disease. Musculoskeletal diseases such as osteoarthritis, tendinopathy and lower back pain are the primary causes of disability and early retirement in people over the age of 65. Currently, there are no approved disease-modifying drugs for these diseases, meaning that physical decline in … Type: | 2 | 7 |
 | ToxGenSolutions BV (TGS) Epigenetics-based diagnostics, prognostics and preventative therapeutics for high-impact chronic pathologies. ToxGenSolutions (TGS) applies toxicogenomic approaches on human health problems to provide the customer with epigenetic biomarker fingerprints for application in novel, more accurate, methods for the particular diagnosis of their need. TGS aims to develop novel and innovative epigenetic profiles hallmarking high-impact chronic and rare neurodevelopmental diseases to serve as early, preclinical, diagnostic verdicts of a disease. With the development of these novel tools, TGS aims to bridge the frequently large gap towards disease progression and therapeutic intervention. TGS provides novel epigenetic diagnostic methods for the early identification of pressing … Type: | 0 | 1 |
 | Medisolutions Medical devices for professionals Type: | 5 | 5 |
 | Masimo Corporation Improving life. Improving patient outcomes and reducing the cost of care. Masimo Corporation (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative non-invasive patient monitoring technologies, including medical devices and a variety of sensors. Our work makes a significant difference in the world by saving, extending and improving the lives of people of all ages in all walks of life. For more than 30 years, our innovative medical technologies and noninvasive patient monitoring solutions have been solving "unsolvable" problems. Our portfolio of clinically validated products provides healthcare providers with the information they need to optimize clinical … Type: | 2 | 6 |
 | City Therapeutics Engineering the future of RNAi-based medicines Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases. Type: | 1 | 39 |
 | Therapeutic Peptides, Inc. Therapeutic Peptides, Inc. is a research company based out of 11725Sun Belt Ct, Baton Rouge, Louisiana, United States. Type: | 0 | 1 |
 | Prostatype Genomics AB Prostatype Genomics offers prostate cancer patients a decision support for the most optimal treatment option. Prostatype Genomics offers prostate cancer patients a decision support for the most optimal treatment option! We developed a test system called 'Prostatype® Test System'. The system is based on a gene expression test, which measures the expression of three carefully selected embryonic stem cell genes in prostate cancer core needle biopsies. In conjunction with currently used clinical parameters, the PrTS predicts overall survival in relation to treatment. The Prostatype® Test System helps to choose the optimal treatment strategy for each patient. This secures quality of … Type: | 0 | 12 |
 | BOOST Pharma Treating the untreatable BOOST Pharma is based on years of collaborative research from Karolinska Institute in Stockholm with the focus on novel cell therapy treatments for Osteogenesis Imperfecta. The research teams of associate professor Cecilia Götherström and professor Magnus Westgren have shown that that treatment with BOOST Cells greatly enhanced the quality of life for patients suffering from this otherwise extremely debilitating disease. Type: | 1 | 8 |
 | ExpreS2ion Biotechnologies Innovative Vaccines for a Healthier World ExpreS2ion Biotechnologies is a clinical-stage DK based biotech company specialised in the development of new vaccines and immunotherapy products. The company has a discovery platform built around a proprietary recombinant expression system, ExpreS2 TM, developed especially for fast and efficient development and production of complex proteins required for innovative new vaccines, immunotherapy and diagnostics. The system also includes functionally modified glycosylation variants. For the clinical Phase III-stage COVID-19 vaccine, ABNCoV2, the Company employs a novel plug-&-play capsid virus-like particle (cVLP) platform, that offers competitive advantages in terms of long-term efficacy, safety, stability, and costing. … Type: | 1 | 21 |
 | LIPUM AB We have developed a biological drug SOL-116 for treatment of chronic inflammatory diseases Lipum aims for better quality of life for the millions suffering from chronic inflammatory diseases, including children. Distressed by pain, disability, and comorbidities many have to leave a normal working life in advance. We intend to increase their quality of life and decrease the considerable health care and societal costs. Inflammatory diseases, Drug development, Preclinical research, Blockbuster drugs, Chronic diseases, and Orphan drug designation Type: | 0 | 15 |
 | bit.bio The Cell Coding Company bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable … Type: | 0 | 203 |
 | LIfT BioSciences The world’s only alpha neutrophil cell therapy platform is being used to destroy all solid tumours. LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary … Type: | 1 | 24 |
 | Pheon Therapeutics Pheon is an Antibody-Drug Conjugate specialist developing next generation ADCs for a range of hard-to-treat cancers. Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments. Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with … Type: | 1 | 23 |
 | Laevoroc Revolutionizing treatment for leukaemia relapse. Spearheading the development of a novel PNP inhibitor poised to revolutionize treatment for leukaemia patients facing relapse post-stem cell transplantation. Oncology Type: | 0 | 3 |
 | Locate Bio Ltd Reshaping rhBMP-2 Perspectives Relieving suffering and improving quality of life with next-generation orthobiologics. Regenerative Medicine, Biomaterials, Medical devices, Drug delivery, biotechnology, BMP2, Programmed Drug Release, and Instructive Tissue Scaffolds Type: | 0 | 22 |
 | Cellbox Labs Industrial organ on chip technology We are developing organs on a chip that are miniature organ replicas outside human body. We are focusing on microbiome and gut on on chip that allows to develop drugs more effective and study biological processes. We are also developing easy to use instrument to run experiments on the chips. Type: | 1 | 12 |
 | Nebu~Flow Transforming Respiratory Drug Delivery Nebu~Flow is developing next generation of nebulisers to unlock delivery of next generation of inhaled drugs Type: | 0 | 17 |
 | Outrun Therapeutics Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases. Type: | 1 | 10 |
 | Accession Therapeutics Limited Developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumour diversity Type: | 2 | 44 |
 | Commit Biologics A pioneer in the activation of the complement system to treat cancer and autoimmune disease. Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit’s Bispecific Complement Engaging (BiCETM) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The … Type: | 1 | 20 |
 | inven Some things cannot be comprised especially quality of life saving drugs, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That`s why, we at Inven, are committed to apply science and our resources, for providing most innovative and quality products. We strive to provide access to safe, effective and affordable medicines to the people who need them. With a strong research oriented work culture, state-of-the-art production facility and end-to-end product development capabilities - Inven is recognized as a leading, ISO 9001-2000 and WHO GMP certified, IV fluid manufacturer in the international and domestic … Type: | 2 | 35 |
 | Duplaco B.V. Reliable chlorella algae producer in the EU Duplaco, based in the Netherlands, reinvented farming to grow clean and rich Chlorella microalgae in a 100% closed system, without disturbing nature. These microalgae are packed with protein, fibers, vitamins, minerals and antioxidants. Big impact, tiny footprint. Microalgae, Biotechnology, Aquaculture, Food supplements, Feed, Tailor made, Fresh, Functional ingredient, Chlorella, Algae, Vegan, and Protein Type: | 4 | 20 |
 | Captain T Cell Off-the-shelf T cells for solid tumor patients Captain T Cell develops first-in-class, efficacy-enhanced T cell therapies against solid tumors that are not addressed by existing treatments. Captain T Cell generates next-generation TCR-T cells with enhanced persistence and the capacity to cope with the hostile tumor microenvironment of difficult-to-treat solid tumors. In addition, the company has established a novel allogeneic platform to enable off-the-shelf treatments of solid tumors. Captain T Cell is based in Schoenefeld/Berlin, Germany, and backed by leading European investors i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H. Captain T Cell was founded by a dedicated … Type: | 1 | 12 |
 | PlaqueTec Ltd. Opening a new frontier in the fight against atherosclerosis PlaqueTec is pursuing a better understanding of the biological mechanisms of coronary artery disease (CAD) to advance the development of precision medicine. CAD, where atherosclerotic plaque build-up narrows or blocks the arteries that supply blood to the heart, is a leading cause of death globally. Current treatment approaches are one-size-fits-all and therefore ineffective for many patients. To address this, PlaqueTec has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression. A more detailed understanding of patient endotypes will … Type: | 0 | 5 |
 | SynOx Therapeutics Our mission is to focus on the unmet clinical needs of patients suffering from Tenosynovial Giant Cell Tumours (TGCT) SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies. Type: | 0 | 21 |
 | AbilityPharma Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. AbilityPharma's is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel. ABTL0812 has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included … Type: | 3 | 23 |
 | Inoviv Accelerating the Development of New Medicines with Targeted Proteomics Inoviv uses a novel technology platform based on targeted proteomics to support pharmaceutical companies with biomarker test development. Proteomics, Biomarker Discovery, Translational Biomarkers, Mass Spectrometry, Targeted Proteomics, Discovery Proteomics, Biomarkers, Precision Medicine, Proteomic Analysis, Proteome Profiling , Quantitative Proteomics, Liquid Chromatography Mass-Spectrometry (LC-MS), Post-Translational Modifications (PTMs), Quantitative Biomarkers, Clinical Proteomics, Immuno-Precipitation Mass Spectrometry (IP-MS), Proteins, LC-MS Proteomics, Proteomics Services, and Protein Identification Type: | 0 | 33 |
 | STALICLA Bringing Precision Medicine to patients with Neurodevelopmental Disorders, including Autism Spectrum Disorder STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments. Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform. STALICLA is currently preparing Phase 2 trials for STP1, STALICLA's first patient subgroup-matched precision treatment. Substance Use Disorder research: … Type: | 0 | 28 |
 | Procavea Biotech Procavea Biotech is on a mission to solve the problem of delivering RNA-based drugs to non-liver tissues. At Procavea we're developing nonviral protein cages as carriers for the delivery of RNA Therapeutics to specific tissues in the body. Protein Engineering and RNA Delivery Type: | 0 | 1 |
 | Mironid® Limited Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our lead programme is in the area of rare genetic kidney disease. Type: | 1 | 17 |
SMB